Citius Pharmaceuticals, Inc.CTXR
Price (close)
$0.58
Market cap
$15.9M
P/E
—
Revenue (TTM)
—
Net income
-$46.3M
Dividend yield
—
1-year total return
-49.7%
Net margin
—
Revenue growth
—
Debt / equity
4.60x
What Citius Pharmaceuticals, Inc. does.
Cranford, New Jersey, is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care
products, with a focus on oncology, anti-infectives in adjunct cancer care and unique prescription products. Our goal generally is to
achieve leading market positions by providing therapeutic products that address unmet medical needs yet have a lower development risk
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $90,000 | $90,000 | $90,000 | — | — | — |
| Net income | -$17.5M | -$23.1M | -$33.6M | -$32.5M | -$39.1M | -$37.4M |
| Free cash flow | -$16.9M | -$24.3M | — | — | — | — |
More on CTXR.
- Citius Pharmaceuticals, Inc. summary
- Citius Pharmaceuticals, Inc. financial statements
- Citius Pharmaceuticals, Inc. key metrics
- Citius Pharmaceuticals, Inc. health scores and style box
- Citius Pharmaceuticals, Inc. earnings
- Citius Pharmaceuticals, Inc. dividends
- Citius Pharmaceuticals, Inc. valuation
- Citius Pharmaceuticals, Inc. ownership and insiders
- Citius Pharmaceuticals, Inc. peers
Figures from Citius Pharmaceuticals, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.